FLT3-ITD and MLL-PTD influence the expression of MDR-1, MRP-1, and BCRP mRNA but not LRP mRNA assessed with RQ-PCR method in adult acute myeloid leukemia

Annals of Hematology

Volumn 93, Issue 4, 2014, Pages 577-593

  Nasilowska Adamska, Barbara ^a   Solarska, Iwona ^a   Paluszewska, Monika ^b   Malinowska, Iwona ^b   Jedrzejczak, Wieslaw W ^b   Warzocha, Krzysztof ^a  

^a INSTITUTE OF HEMATOLOGY AND TRANSFUSION MEDICINE   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

Acute myeloid leukemia; Drug resistance; FLT3 ITD; MLL PTD

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; CD135 ANTIGEN; CLADRIBINE; CYTARABINE; DAUNORUBICIN; FLUDARABINE; IDARUBICIN; LUNG RESISTANCE PROTEIN; MESSENGER RNA; MITOXANTRONE; MIXED LINEAGE LEUKEMIA PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTINUOUS INFUSION; FEMALE; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; INTERNAL TANDEM DUPLICATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OVERALL SURVIVAL; PARTIAL TANDEM DUPLICATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE RISK; UNIVARIATE ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ATP-BINDING CASSETTE TRANSPORTERS; DISEASE-FREE SURVIVAL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE DUPLICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NEOPLASM PROTEINS; P-GLYCOPROTEIN; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; VAULT RIBONUCLEOPROTEIN PARTICLES; YOUNG ADULT;

EID: 84896389165     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-013-1898-7     Document Type: Article

References (89)

1. Estey E, Döhner H (2006) Acute myeloid leukemia. Lancet 368:1894-1907
2. Fröhling S, Scholl C, Gilliland DG, Levine RL (2005) Genetics of myeloid malignancies - pathogenetic and clinical implications. J Clin Oncol 23:6285-6295
3. Mrozek K, Heerema NA, Bloomfield CD (2004) Cytogenetics in acute leukemia. Blood Rev 18:115-136
4. Grimwade D (2001) The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol 14:497-529
5. Grimwade D, Hillis RK (2009) Independent prognostic factors for AML outcome. Hematology p 389-95
6. Döhner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood 115:453-474
7. Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD (2008) Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumors of haematopoietic and lymphoid tissues. IARC, Lyon, pp 110-123
8. Schlenk RF, Döhner K, Krauter J, Fröhling S, Corbacioglu A, Bullinger L, Habdank M, Späth D, Morgan M, Benner A, Schlegelberger B, Heil G, Ganser A, Döhner H, for the German-Austrian Acute Myeloid Leukemia Study Group (2008) Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 358:1909-1918
9. Marcucci G, Haferlach T, Döhner H (2011) Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 29:475-486
10. Döhner H (2007) Implication of the molecular characterization of acute myeloid leukemia. Hematology p 412-9
11. Grossman V, Schnittger S, Kohlmann A, Christiane E, Roller A, Dicker F, Schmid C, Wendtner C-M, Staib P, Serve H, Kreuzer K-A, Kem W, Haferlach T, Haberlach C (2012) A novel hierarchical prognostic model of AML solely based on molecular mutations. Blood 120:2963-2972
12. Kelly LM, Gilliland DG (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3:179-198
13. Estey EH (2013) Acute myeloid leukemia: 2013 update on risk stratification and management. Am J Hematol 88:318-327
14. Rosnet O, Mattei MG, Marchetto S, Birnbaum D (1991) Isolation and chromosomal localization of a novel FMS-like tyrosine kinase gene. Genomics 9:380-385
15. Yokota S, Kiyoi H, Nakao M, Iwai T, Misawa S, Okuda T, Sonoda Y, Abe T, Kashima K, Matsuo Y, Naoe T (1997) Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia 11:1605-1609
16. Whitman SP, Ruppert AS, Radmacher MD, Mrozek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE, Larson RA, Caligiuri MA, Marcucci G, Bloomfield CD (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111:1552-1559
17. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C, Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R, Ueda R (1999) Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93:3074-3080
18. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, Carroll AJ, Mrozek K, Vardiman JW, George SL, Kolitz JE, Larson RA, Bloomfield CD, Caligiuri MA (2001) Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a cancer and leukemia group B study. Cancer Res 61:7233-7239
19. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AL, Goldstone AH, Linch DC (2001) The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759
20. Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K (2002) Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 100:4372-4380
21. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T (2002) Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335
22. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland CM, Serve H, Büchner T, Haferlach T, Hiddemann W (2002) Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59-66
23. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, Linch DS, on behalf of the Medical Research Council Adult Leukaemia Working Party (2008) The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776-2784
24. Pratcorona M, Brunet S, Nomdedéu J, Ribera JM, Tormo M, Duarte R, Escoda L, Guárdia R, de Llano MPQ, Salamero O, Bargay J, Pedro C, Marti JM, Torrebadell M, Diaz-Beyá M, Camós M, Colomer D, Hoyos M, Sierra J, Esteve J, on behalf of the Grupo Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas Mieloblásticas (2013) Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood 121:2734-2738
25. Basecke J, Whelan JT, Griesinger F, Bertrand FE (2006) The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol 135:438-449
26. Caligiuri MA, Strout MP, Lawrence D, Arthur DC, Baer MR, Yu F, Knuutila S, Mrozek K, Oberkircher AR, Marcucci G, de la Chapelle A, Elonen E, Block AMW, Rao PN, Herzig GP, Powell BL, Ruutu T, Schiffer CA, Bloomfield CD (1998) Rearrangement of ALL1 (MLL) in acute myeloid leukemia with normal cytogenetics. Cancer Res 58:55-59
27. Döhner K, Tobis K, Ulrich R, Fröhling S, Benner A, Schlenk RF, Döhner H (2002) Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 20:3254-3261
28. Tirebelli M, Geromin A, Michelluti A, Cavallin M, Pianta A, Fabbro D, Russo D, Damante G, Fanin R, Damiani D (2011) Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. Cancer 117:2156-2162
29. Robak T, Wierzbowska A (2009) Clin Ther 31:2349-2370
30. Kindler T, Lipka DB, Fischer T (2010) FLT3 as therapeutic target in AML: still challenging after all these years. Blood 116:169-178
31. Benderra Z, Faussat AM, Sayada L, Perrot JY, Tang R, Chaoui D, Morjani H, Marzac C, Marie JP, Legrand O (2005) MRP3, BCRP, and P-glycoprotein activities are prognostic factors in adult acute myeloid leukemia. Clin Cancer Res 11:7764-7772
32. Laupeze B, Amiot L, Drenou B, Bernard M, Branger B, Grosset JM, Lamy T, Fauchet R, Fardel O (2002) High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 116:834-838
33. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JB, Forman SJ, Appelbaum FR (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083
34. Holowiecki J, Grosicki S, Giebel S, Robak T, Kyrcz-Krzemien S, Kuliczkowski K, Skotnicki AB, Hellmann A, Sulek K, Dmoszynska A, Kloczko J, Jedrzejczak WW, Zdziarska B, Warzocha K, Zawilska K, Komarnicki M, Kielbinski M, Piatkowska-Jakubas B, Wierzbowska A, Wach M, Haus O (2012) Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol 30:2441-2448
35. Kottaridis PD, Gale RE, Langabeer SE, Frew ME, Bowen DT, Linch DC (2002) Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. Blood 100:2393-2398
36. Poirel H, Rack K, Delabesse E, Radford-Weiss I, Troussard X, Debert C, Leboeuf D, Bastard C, Picard F, Veil-Buzyn A, Flandrin G, Bernard O, Macintyre E (1996) Incidence and characterization of MLL gene (11q23) rearrangements in acute myeloid leukemia M1 and M5. Blood 87:2496-2505
37. Beck J, Handgretinger R, Dopfer R, Klingebiel T, Niethammer D, Gekeler V (1995) Expression of MDR1, MRP1, topoisomerase IIα/β, and cyclin A in primary or relapsed states of acute lymphoblastic leukemias. Br J Haematology 89:356-363
38. Uggla B, Stahl E, Wagsater D, Paul C, Karlsson MG, Sirsjo A, Tidefelt U (2005) BCRP mRNA expression v. clinical outcome in 40 adult AML patients. Leukemia Res 29:141-146
39. Schaich M, Soucek S, Thiede C, Ehninger G, Illmer T, on behalf of the SHG AML96 Study Group (2005) MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 128:324-332
40. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30:36-46
41. van Dongen JJM, Macintyre EA, Gabert JA, Delabesse E, Rossi V, Saglio G, Gottardi E, Rambaldi A, Dotti G, Griesinger F, Parreira A, Gameiro P, González Diáz M, MalecM LAW, San Miguel JF, Biondi A (1999) Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: investigation of minimal residual disease in acute leukemia. Leukemia 13:1901-1928
42. Mrozek K, Prior TW, Edwards C, Marcucci G, Carroll AJ, Snyder PJ, Koduru PRK, Theil KS, Pettenati MJ, Archer KJ, Caligiuri MA, Vardiman JW, Kolitz JE, Larson RA, Bloomfield CD (2001) Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 19:2482-2492
43. Grimwade D (2002) Screening for core binding factor gene rearrangements in acute myeloid leukemia. Leukemia 16:964-969
44. Olsen LH, Nyvold CG, Aggerholm A, Norgaard JM, Guldberg P, Hokland P (2005) Delineation and molecular characterization of acute myeloid leukemia patients with coduplication of FLT3 and MLL. Eur J Haematol 75:185-192
45. Ansari-Lari M, Yang C-F, Tinawi-Aljundi R, Cooper L, Long P, Allan RH, Borowitz MJ, Berg KD, Murphy KM (2004) FLT3 mutations in myeloid sarcoma. Br J Haematol 126:785-791
46. Seedhouse CH, Hunter HM, Lloyd-Lewis B, Massip AM, Pallis M, Carter GI, Grundy M, Shang S, Russell NH (2006) DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412. Leukemia 20:2130-2136
47. Bower M, Parry P, Carter M, Lillington DM, Amess J, Lister TA, Evans CA, Young BD (1994) Prevalence and clinical correlations of MLL gene rearrangements in AML-M4/5. Blood 84:3776-3780
48. Willman CL (1997) The prognostic significance of the expression and function of multidrug resistance transporter proteins in acute myeloid leukemia: studies of the Southwest Oncology Group Leukemia Research Program. Semin Hematol 34:25-33
49. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, Wiemer EA (2003) Vaults: a ribonucleoprotein particle involved in drug resistance? Oncogene 22:7458-7467
50. van Zon A, Mossink MH, Schoester M, Scheper RJ, Sonneveld P, Wiemer EA (2004) Efflux kinetics and intracellular distribution of daunorubicin are not affected by major vault protein/lung resistance-related protein (vault) expression. Cancer Res 64:4887-4892
51. Legrand O, Simonin G, Zittoun R, Marie JP (1998) Lung resistance protein (LRP) gene expression in adult acute myeloid leukemia: a critical evaluation by three techniques. Leukemia 12:1367-1374
52. Baldus C, Fietz T, Rieder H, Schwartz S, Thiel E, Knauf W (2001) MDR-1 expression and deletions of chromosomes 7 and 5 (Q) separately indicate adverse prognosis in AML. Leuk Lymphoma 40:613-623
53. Leith CP, Kopecky KJ, Godwin J, McConnell T, Slovak ML, Chen IM, Head DR, Appelbaum FR, Willman CL (1997) Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 89:3323-3329
54. de Figueiredo Pontes LL, Pintao MC, Oliveira LC, Dalmazzo LF, Jacomo RH, Garcia AB, Falcão RP, Rego EM (2008) Determination of P-glycoprotein, MDR-related protein 1, breast cancer resistance protein, and lung-resistance protein expression in leukemic stem cells of acute myeloid leukemia. Cytometry B Clin Cytom 74B:163-168
55. Benderra Z, Faussat AM, Sayada L, Perrot JY, Chaoui D, Marie JP, Legrand O (2004) Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Clin Cancer Res 10:7896-7902
56. Damiani D, Tiribelli M, Calistri E, Geromin A, Chiarvesio A, Michelutti A, Cavallin M, Fanin R (2006) The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica 91:825-828
57. van den Heuvel-Eibrink MM, van der Holt B, Burnett AK, Knauf WU, Fey MF, Verhoef GEG, Vellenga E, Ossenkoppele GJ, Löwenberg B, Sonneveld P (2007) CD34-related co expression of MDR1 and BCRP indicates a clinically resistant phenotype in patients with acute myeloid leukemia (AML) of older age. Ann Hematol 86:329-337
58. --phenotypes with shorter survival. Groupe d'Etude Immunologique des Léucemies (GEIL). Leukemia 6:393-399
59. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D (1992) Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 79:473-476
60. Selleri C, Notaro R, Catalano L, Fontana R, Del Vecchio L, Rotoli B (1992) Prognostic irrelevance of CD34 in acute myeloid leukaemia. Br J Haematol 82:479-1
61. Ciolli S, Leoni F, Caporale R, Pascarella A, Salti F, Rossi-Ferrini P (1993) CD34 expression fails to predict the outcome in adult acute myeloid leukemia. Haematologica 78:151-155
62. Marzac C, Teyssandier I, Calendini O, Perrot JY, Faussat AM, Tang R, Casadevall N, Marie JP, Legrand O (2006) Flt3 internal tandem duplication and P-glycoprotein functionality in 171 patients with acute myeloid leukemia. Clin Cancer Res 12:7018-7024
63. Smeets ME, Raymakers RA, Vierwinden G, Pennings AH, Wessels H, de Wiltte I (1999) Triggering noncycling hematopoietic progenitors and leukemic blasts to proliferate increases anthracycline retention and toxicity by down regulating multidrug resistance. Blood 94:2414-2423
64. Olesen LH, Aggerholm A, Andersen BL, Nyvold CG, Guldberg P, Norgaard JM, Hokland P (2005) Molecular typing of adult acute myeloid leukaemia: significance of translocations, tandem duplications, methylation and selective gene expression profiling. Br J Haematol 131:457-467
65. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Müller C, Grüning W, Kratz-Albers K, Serve S, Steur C, Büchner T, Kienast J, Kanakura Y, Berdel WE, Serve H (2000) Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96:3907-3914
66. Tse KF, Mukherjee G, Small D (2000) Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14:1766-1776
67. Scheijen B, Ngo HT, Kang H, Griffin JD (2004) FLT3 receptors with internal tandem duplications promote cell viability and proliferation by signaling through Foxo proteins. Oncogene 23:3338-3349
68. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T (2000) Tandem duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624-631
69. Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100:1532-1542
70. Lee JT Jr, Steelman LS, McCubrey JA (2004) Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64:8397-8404
71. Tazzari PL, Capellini A, Ricci F, Evangelisti C, Papa V, Grafone T, Martinelli G, Conte R, Cocco L, McCubrey JA, Martelli AM (2007) Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts. Leukemia 21:427-438
72. Scotto KW (2003) Transcriptional regulation of ABC drug transporters. Oncogene 22:7496-7511
73. Seedhouse CH, Grundy M, White P, Li Y, Fisher J, Yakunina D, Moorman AV, Hoy T, Russell N, Burnett A, Pallis M (2007) Sequential influences of leukemia-specific and genetic factors on P-glycoprotein expression in blasts from 817 patients entered into the National Cancer Research Network acute myeloid leukemia 14 and 15 trials. Clin Cancer Res 13:7059-7066
74. Labialle S, Gayet L, Marthinet E, Rigal D, Baggetto LG (2002) Transcriptional regulators of the human multidrug resistance 1 gene: recent views. Biochem Pharmacol 64:943-948
75. Licht T, Fiebig HH, Bross KJ, Herrmann F, Berger DP, Shoemaker R, Mertelsmann R (1991) Induction of multiple-drug resistance during anti-neoplastic chemotherapy in vitro. Int J Cancer 49:630-637
76. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM (1990) Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human renal carcinoma cells. J Biol Chem 265:221-226
77. Comerford KM, Wallace TJ, Karhausen J, JLouis NA, Montalto MC, Colgan SP (2002) Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1). Cancer Res 62:3387-3394
78. Kantharidis P, El-Osta A, deSilva M, Wall DM, Hu XF, Slater A, Nadalin G, Parkin JD, Zalcberg JR (1997) Altered methylation of the human MDR1 promoters associated with acquired multidrug resistance. Clin Cancer Res 3:2025-2032
79. Byrd JC, Mrozek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, Pettenati MJ, Patil SR, Rao KW, Watson MS, Koduru PR, Moore JO, Stone RM, Mayer RJ, Feldman EJ, Davey FR, Schiffer CA, Larson RA, Bloomfield CD (2002) Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336
80. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, Rees J, Hann I, Stevens R, Burnett A, Goldstone A (1998) The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333
81. Leith CP, Kopecky KJ, Chen IM, Eijdems L, Slovak ML, McConnell TS, Head DR, Weick J, Grever MR, Appelbaum FR, Willman CL (1999) Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. Blood 94:1086-1099
82. Pearson L, Leith CP, Duncan MH, Chen IM, McConnell T, Trinkaus K, Foucar K, Willman CL (1996) Multidrug resistance-1 (MDR1) expression and functional dye/drug efflux is highly correlated with the t(8;21) chromosomal translocation in pediatric acute myeloid leukemia. Leukemia 10:1274-1282
83. Guenther MG, Jenner RG, Chevalier B, Nakamura T, Croce CM, Canaani E, Young RA (2005) Global and Hox-specific roles for the MLL1 methyltransferase. Proc Natl Acad Sci U S A 102:8603-8608
84. Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM (2012) Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resistance Updates 15:62-69
85. Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett J, Rowe JM, Lazarus HM, Luger S, Tallman MS (2010) Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood 116:4077-4085
86. Pallis M, Turzanski J, Higashi Y, Russel N (2002) P-glycoprotein in acute myeloid leukemia: therapeutic implications of its association with both a multidrug resistant and an apoptosis resistant phenotype. Leukemia Lymphoma 43:1221-1228
87. Pallis M, Russell N (2000) P-glycoprotein plays a drug-efflux-independent role in augmenting cell survival in acute myeloblastic leukemia and is associated with modulation of a sphingomyelin-ceramide apoptotic pathway. Blood 95:2897-2904
88. Hunter MH, Pallis M, Seedhouse CH, GrundyM GC, Russe NH (2004) The expression of P-glycoprotein in AML cells with FLT3 internal tandem duplication is associated with reduced apoptosis in response to FLT3 inhibitors. Br J Haematol 127:26-33
89. Fine R, Chambers T, Sachs C (1996) P-glycoprotein, multidrug resistance and protein kinase C. Oncologist 1:261-268